ganirelix
(GJNXBNATEDXMAK-PFLSVRRQSA-N)
Structure
- SMILES
- CCNC(=NCCCC[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N)C)CCCCN=C(NCC)NCC)CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](Cc1ccc2c(c1)cccc2)NC(=O)C)Cc1ccc(cc1)Cl)Cc1cccnc1)CO)Cc1ccc(cc1)O)NCC
- Type(s)
- Approved
- ATC code(s)
- H01CC01
- Molecular Formula:
- C80H113ClN18O13
- Molecular Weight:
- 1570.320
- Log P:
- 7.9926
- Hydrogen Bond Acceptor:
- 31
- Hydrogen Bond Donor:
- 16
- TPSA:
- 451.49
- CAS Number(s):
- 123246-29-7; 124904-93-4
Synonym(s)
1.
ganirelix
2.
Antagon
3.
GnRH, N-Ac-2-Nal(1)-4-Cl-Phe(2)-3-Pal(3)-Et2-hArg(6,8)-AlaNH2(10)-
4.
LHRH, N-acetyl-2-naphthylalanyl(1)-(4-chlorophenylalanyl)(2)-3-pyrdinylalanyl(3)-diethylhomoarginyl(6,8)-alaninamide(10)-
5.
LHRH,N-Ac-2-Nal(1)-4-Cl-Phe(2)-3-Pal(3)-Et2-hArg(6,8)-AlaNH2(10)-
6.
N-Ac-(2-naphthyl)Ala-2-(4-Cl-Phe)-3-(3-pyridinyl-Ala)-6,8-Et2-hArg-10-AlaNH2-LHRH
7.
N-acetyl-3-(2-naphthyl)-D-alanyl-p-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N(sup 6)-(N,N'-diethylamidino)-D-lysyl-L-leucyl-N(sup 6)-(N,N'-diethylamidino)-L-lysyl-L-prolyl-D-alaninamide diacetate (salt)
8.
RS 26306
9.
RS-26306
10.
RS-26306-298
11.
ganirelix acetate
12.
ganirelix diacetate
13.
orgalutran
External Link(s)
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Product quality issue | FAERS: 8 | US FAERS | |
| 2 | Product storage error | FAERS: 8 | US FAERS | |
| 3 | Drug ineffective | FAERS: 6 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 4 | Cyanosis | FAERS: 3 | US FAERS | |
| 5 | Dehydration | FAERS: 3 | US FAERS | |
| 6 | Vomiting | FAERS: 3 | US FAERS | |
| 7 | Anaphylactic shock | FAERS: 1 | US FAERS | |
| 8 | Erythema | FAERS: 1 | US FAERS | |
| 9 | Inappropriate schedule of drug administration | FAERS: 1 | US FAERS | |
| 10 | Incorrect dose administered | FAERS: 1 | US FAERS | |
| 11 | Maternal exposure before pregnancy | FAERS: 1 | US FAERS | |
| 12 | Multiple sclerosis relapse | FAERS: 1 | US FAERS | |
| 13 | Musculoskeletal Pain | FAERS: 1 | US FAERS | |
| 14 | Respiratory distress | FAERS: 1 | US FAERS | |
| 15 | Syncope | FAERS: 1 | US FAERS | |
| 16 | Ventricular Dysfunction | FAERS: 1 | US FAERS |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.